Drug intelligence / Profile preview

DA-302168S

Development stage: Phase 3
Lead developer: Chengdu Di'ao Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DA-302168S is an investigational small molecule drug developed by Chengdu Di'ao Pharmaceutical Group. It acts as an agonist of the glucagon-like peptide 1 receptor (GLP-1R), a mechanism commonly targeted for the treatment of metabolic diseases such as obesity and type 2 diabetes mellitus. The drug is being evaluated primarily for oral administration, with clinical trials focused on its safety, tolerability, pharmacokinetics, and pharmacodynamics in overweight or obese subjects. As of April 2025, its highest global development status is Phase 2 for obesity and type 2 diabetes mellitus[1][3][4].

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on DA-302168S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-302168S.

Explore the full profile